Literature DB >> 21296109

The pro- and anti-inflammatory properties of the cytokine interleukin-6.

Jürgen Scheller1, Athena Chalaris, Dirk Schmidt-Arras, Stefan Rose-John.   

Abstract

Interleukin-6 is a cytokine not only involved in inflammation and infection responses but also in the regulation of metabolic, regenerative, and neural processes. In classic signaling, interleukin-6 stimulates target cells via a membrane bound interleukin-6 receptor, which upon ligand binding associates with the signaling receptor protein gp130. Gp130 dimerizes, leading to the activation of Janus kinases and subsequent phosphorylation of tyrosine residues within the cytoplasmic portion of gp130. This leads to the engagement of phosphatase Src homology domains containing tyrosin phosphatase-2 (SHP-2) and activation of the ras/raf/Mitogen-activated protein (MAP) kinase (MAPK) pathway. In addition, signal transducer and activator of transcription factors are recruited, which are phosphorylated, and consequently dimerize whereupon they translocate into the nucleus and activate target genes. Interestingly, only few cells express membrane bound interleukin-6 receptor whereas all cells display gp130 on the cell surface. While cells, which only express gp130, are not responsive to interleukin-6 alone, they can respond to a complex of interleukin-6 bound to a naturally occurring soluble form of the interleukin-6 receptor. Therefore, the generation of soluble form of the interleukin-6 receptor dramatically enlarges the spectrum of interleukin-6 target cells. This process has been named trans-signaling. Here, we review the involvement of both signaling modes in the biology of interleukin-6. It turns out that regenerative or anti-inflammatory activities of interleukin-6 are mediated by classic signaling whereas pro-inflammatory responses of interleukin-6 are rather mediated by trans-signaling. This is important since therapeutic blockade of interleukin-6 by the neutralizing anti-interleukin-6 receptor monoclonal antibody tocilizumab has recently been approved for the treatment of inflammatory diseases. This article is part of a Special Issue entitled: 11th European Symposium on Calcium. 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21296109     DOI: 10.1016/j.bbamcr.2011.01.034

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  1042 in total

Review 1.  Regulation of myelopoiesis by proinflammatory cytokines in infectious diseases.

Authors:  Yukino Chiba; Izuru Mizoguchi; Hideaki Hasegawa; Mio Ohashi; Naoko Orii; Taro Nagai; Miyaka Sugahara; Yasunori Miyamoto; Mingli Xu; Toshiyuki Owaki; Takayuki Yoshimoto
Journal:  Cell Mol Life Sci       Date:  2017-12-07       Impact factor: 9.261

2.  IL-6-mediated signaling pathways limit Chlamydia muridarum infection and exacerbate its pathogenicity in the mouse genital tract.

Authors:  Xin Sun; Qi Tian; Luying Wang; Min Xue; Guangming Zhong
Journal:  Microbes Infect       Date:  2017-08-31       Impact factor: 2.700

Review 3.  Müller cells and diabetic retinopathy.

Authors:  Brandon A Coughlin; Derrick J Feenstra; Susanne Mohr
Journal:  Vision Res       Date:  2017-09-05       Impact factor: 1.886

4.  Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling.

Authors:  Mathew T Mizwicki; Milan Fiala; Larry Magpantay; Najib Aziz; James Sayre; Guanghao Liu; Avi Siani; Derrick Chan; Otoniel Martinez-Maza; Madhuri Chattopadhyay; Antonio La Cava
Journal:  Am J Neurodegener Dis       Date:  2012-11-21

5.  Short-term but not long-term hypoglycaemia enhances plasma levels and hepatic expression of HSP72 in insulin-treated rats: an effect associated with increased IL-6 levels but not with IL-10 or TNF-α.

Authors:  Mirna Stela Ludwig; Vânia Cibele Minguetti-Câmara; Thiago Gomes Heck; Sofia Pizzato Scomazzon; Patrícia Renck Nunes; Roberto Barbosa Bazotte; Paulo Ivo Homem de Bittencourt
Journal:  Mol Cell Biochem       Date:  2014-08-06       Impact factor: 3.396

Review 6.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

7.  Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth.

Authors:  Romuald Girard; Hussein A Zeineddine; Janne Koskimäki; Maged D Fam; Ying Cao; Changbin Shi; Thomas Moore; Rhonda Lightle; Agnieszka Stadnik; Kiranj Chaudagar; Sean Polster; Robert Shenkar; Ryan Duggan; David Leclerc; Kevin J Whitehead; Dean Y Li; Issam A Awad
Journal:  Circ Res       Date:  2018-05-02       Impact factor: 17.367

Review 8.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

9.  Effects of simvastatin on the function of splenic CD4+ and CD8+ T cells in sepsis mice.

Authors:  Bingbing Kong; Xiaofeng Wang; Wenping Yang; Xin Zhao; Rong Zhang; Yu Wang
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

10.  Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain.

Authors:  Iain L Campbell; Maria Erta; Sue Ling Lim; Ricardo Frausto; Ulrike May; Stefan Rose-John; Jürgen Scheller; Juan Hidalgo
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.